157 related articles for article (PubMed ID: 27546290)
1. Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma.
Pasqualucci L; Zhang B
Semin Cancer Biol; 2016 Aug; 39():26-31. PubMed ID: 27546290
[TBL] [Abstract][Full Text] [Related]
2. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.
Ramachandiran S; Adon A; Guo X; Wang Y; Wang H; Chen Z; Kowalski J; Sunay UR; Young AN; Brown T; Mar JC; Du Y; Fu H; Mann KP; Natkunam Y; Boise LH; Saavedra HI; Lossos IS; Bernal-Mizrachi L
Int J Cancer; 2015 May; 136(10):2341-51. PubMed ID: 25359525
[TBL] [Abstract][Full Text] [Related]
3. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
[TBL] [Abstract][Full Text] [Related]
5. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
[TBL] [Abstract][Full Text] [Related]
6. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
[TBL] [Abstract][Full Text] [Related]
7. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
Eluard B; Nuan-Aliman S; Faumont N; Collares D; Bordereaux D; Montagne A; Martins I; Cagnard N; Caly M; Taoui O; Lordello L; Lehmann-Che J; Tesson B; Martinez-Climent JA; Copie-Bergman C; Haioun C; Tilly H; Bonsang B; Vincent-Salomon A; Jais JP; Jardin F; Leroy K; Maiuri MC; Kroemer G; Molina TJ; Feuillard J; Baud V
Blood; 2022 Jan; 139(3):384-398. PubMed ID: 34232979
[TBL] [Abstract][Full Text] [Related]
8. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.
Nogai H; Wenzel SS; Hailfinger S; Grau M; Kaergel E; Seitz V; Wollert-Wulf B; Pfeifer M; Wolf A; Frick M; Dietze K; Madle H; Tzankov A; Hummel M; Dörken B; Scheidereit C; Janz M; Lenz P; Thome M; Lenz G
Blood; 2013 Sep; 122(13):2242-50. PubMed ID: 23869088
[TBL] [Abstract][Full Text] [Related]
9. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
[TBL] [Abstract][Full Text] [Related]
10. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Compagno M; Lim WK; Grunn A; Nandula SV; Brahmachary M; Shen Q; Bertoni F; Ponzoni M; Scandurra M; Califano A; Bhagat G; Chadburn A; Dalla-Favera R; Pasqualucci L
Nature; 2009 Jun; 459(7247):717-21. PubMed ID: 19412164
[TBL] [Abstract][Full Text] [Related]
11. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.
Pulvino M; Liang Y; Oleksyn D; DeRan M; Van Pelt E; Shapiro J; Sanz I; Chen L; Zhao J
Blood; 2012 Aug; 120(8):1668-77. PubMed ID: 22791293
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
[TBL] [Abstract][Full Text] [Related]
14. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.
Guo X; Koff JL; Moffitt AB; Cinar M; Ramachandiran S; Chen Z; Switchenko JM; Mosunjac M; Neill SG; Mann KP; Bagirov M; Du Y; Natkunam Y; Khoury HJ; Rossi MR; Harris W; Flowers CR; Lossos IS; Boise LH; Dave SS; Kowalski J; Bernal-Mizrachi L
Oncogene; 2017 Jul; 36(29):4224-4232. PubMed ID: 28368397
[TBL] [Abstract][Full Text] [Related]
15. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
[TBL] [Abstract][Full Text] [Related]
17. B-cell receptor signaling in diffuse large B-cell lymphoma.
Young RM; Shaffer AL; Phelan JD; Staudt LM
Semin Hematol; 2015 Apr; 52(2):77-85. PubMed ID: 25805587
[TBL] [Abstract][Full Text] [Related]
18. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
Lenz G; Davis RE; Ngo VN; Lam L; George TC; Wright GW; Dave SS; Zhao H; Xu W; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Chan WC; Staudt LM
Science; 2008 Mar; 319(5870):1676-9. PubMed ID: 18323416
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological implications of nuclear factor κB signal pathway activation in diffuse large B-cell lymphoma.
Zhao Q; Fu W; Jiang H; Du J; Zhang C; Xi H; Zhou F; Li R; Hou J
Hum Pathol; 2015 Apr; 46(4):524-31. PubMed ID: 25636172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]